<!DOCTYPE html>
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>HPC | Blood Bank</title>
<meta name="author" content="Brett M. Rice">
<meta name="description" content="Hematopoietic Progenitor Cell (HPC) Transplantation, often called stem cell transplant or bone marrow transplant, shares some principles with solid organ transplantation (like HLA matching), the...">
<meta name="generator" content="bookdown 0.42 with bs4_book()">
<meta property="og:title" content="HPC | Blood Bank">
<meta property="og:type" content="book">
<meta property="og:description" content="Hematopoietic Progenitor Cell (HPC) Transplantation, often called stem cell transplant or bone marrow transplant, shares some principles with solid organ transplantation (like HLA matching), the...">
<meta name="twitter:card" content="summary">
<meta name="twitter:title" content="HPC | Blood Bank">
<meta name="twitter:description" content="Hematopoietic Progenitor Cell (HPC) Transplantation, often called stem cell transplant or bone marrow transplant, shares some principles with solid organ transplantation (like HLA matching), the...">
<!-- JS --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://kit.fontawesome.com/6ecbd6c532.js" crossorigin="anonymous"></script><script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="libs/bootstrap-4.6.0/bootstrap.min.css" rel="stylesheet">
<script src="libs/bootstrap-4.6.0/bootstrap.bundle.min.js"></script><script src="libs/bs3compat-0.9.0/transition.js"></script><script src="libs/bs3compat-0.9.0/tabs.js"></script><script src="libs/bs3compat-0.9.0/bs3compat.js"></script><link href="libs/bs4_book-1.0.0/bs4_book.css" rel="stylesheet">
<script src="libs/bs4_book-1.0.0/bs4_book.js"></script><meta name="google-adsense-account" content="ca-pub-1344282930858290">
<script async src="https://www.googletagmanager.com/gtag/js?id=G-JERRQQFPF4"></script><script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'G-JERRQQFPF4');
    </script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- CSS --><style type="text/css">
    
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  </style>
<link rel="stylesheet" href="style.css">
<link rel="stylesheet" href="toc.css">
</head>
<body data-spy="scroll" data-target="#toc">

<div class="container-fluid">
<div class="row">
  <header class="col-sm-12 col-lg-3 sidebar sidebar-book"><a class="sr-only sr-only-focusable" href="#content">Skip to main content</a>

    <div class="d-flex align-items-start justify-content-between">
      <h1>
        <a href="index.html" title="">Blood Bank</a>
      </h1>
      <button class="btn btn-outline-primary d-lg-none ml-2 mt-1" type="button" data-toggle="collapse" data-target="#main-nav" aria-expanded="true" aria-controls="main-nav"><i class="fas fa-bars"></i><span class="sr-only">Show table of contents</span></button>
    </div>

    <div id="main-nav" class="collapse-lg">
      <form role="search">
        <input id="search" class="form-control" type="search" placeholder="Search" aria-label="Search">
</form>

      <nav aria-label="Table of contents"><h2>Table of contents</h2>
        <ul class="book-toc list-unstyled">
<li><a class="" href="index.html">About</a></li>
<li><a class="" href="content-areas.html">Content Areas</a></li>
<li><a class="" href="author.html">Author</a></li>
<li><a class="" href="ascp-boc.html">ASCP BOC</a></li>
<li><a class="" href="reading-list.html">Reading List</a></li>
<li class="book-part">Blood Products</li>
<li><a class="" href="donors.html">Donors</a></li>
<li><a class="" href="qualification.html">Qualification</a></li>
<li><a class="" href="processing.html">Processing</a></li>
<li><a class="" href="adverse-reactions-1.html">Adverse Reactions</a></li>
<li><a class="" href="special-donations-1.html">Special Donations</a></li>
<li><a class="" href="processing-1.html">Processing</a></li>
<li><a class="" href="fda-aabb-requirements.html">FDA, AABB Requirements</a></li>
<li><a class="" href="testing.html">Testing</a></li>
<li><a class="" href="labeling.html">Labeling</a></li>
<li><a class="" href="storage.html">Storage</a></li>
<li><a class="" href="anticoagulantsadditives.html">Anticoagulants/Additives</a></li>
<li><a class="" href="temperature-requirements.html">Temperature Requirements</a></li>
<li><a class="" href="transportation.html">Transportation</a></li>
<li><a class="" href="stored-products.html">Stored Products</a></li>
<li><a class="" href="expiration.html">Expiration</a></li>
<li><a class="" href="blood-components.html">Blood Components</a></li>
<li><a class="" href="red-blood-cells.html">Red Blood Cells</a></li>
<li><a class="" href="cryoprecipitated-ahf.html">Cryoprecipitated AHF</a></li>
<li><a class="" href="platelets.html">Platelets</a></li>
<li><a class="" href="plasma.html">Plasma</a></li>
<li><a class="" href="granulocytes.html">Granulocytes</a></li>
<li><a class="" href="wbc-reduced-components.html">WBC-Reduced Components</a></li>
<li><a class="" href="frozendeglycerolized-rbcs.html">Frozen/Deglycerolized RBCs</a></li>
<li><a class="" href="apheresis-products.html">Apheresis Products</a></li>
<li><a class="" href="fractionation-products.html">Fractionation Products</a></li>
<li><a class="" href="whole-blood.html">Whole Blood</a></li>
<li><a class="" href="washed-rbcs.html">Washed RBCs</a></li>
<li><a class="" href="rejuvenated-rbcs.html">Rejuvenated RBCs</a></li>
<li><a class="" href="irradiated-components.html">Irradiated Components</a></li>
<li><a class="" href="hematopoietic-progenitors.html">Hematopoietic Progenitors</a></li>
<li><a class="" href="blood-component-qc.html">Blood Component QC</a></li>
<li class="book-part">Blood Group Systems</li>
<li><a class="" href="genetics.html">Genetics</a></li>
<li><a class="" href="basic.html">Basic</a></li>
<li><a class="" href="molecular.html">Molecular</a></li>
<li><a class="" href="blood-group-inheritance.html">Blood Group Inheritance</a></li>
<li><a class="" href="biochemistryantigens.html">Biochemistry/Antigens</a></li>
<li><a class="" href="abo.html">ABO</a></li>
<li><a class="" href="lewis.html">Lewis</a></li>
<li><a class="" href="rh.html">Rh</a></li>
<li><a class="" href="mns.html">MNS</a></li>
<li><a class="" href="p1pkglobosidep.html">P1PK/Globoside(P)</a></li>
<li><a class="" href="ii.html">Ii</a></li>
<li><a class="" href="kell.html">Kell</a></li>
<li><a class="" href="kidd.html">Kidd</a></li>
<li><a class="" href="duffy.html">Duffy</a></li>
<li><a class="" href="lutheran.html">Lutheran</a></li>
<li><a class="" href="other-blood-groups.html">Other Blood Groups</a></li>
<li><a class="" href="high-prevalence-antigens.html">High Prevalence Antigens</a></li>
<li><a class="" href="low-prevalence-antigens.html">Low Prevalence Antigens</a></li>
<li><a class="" href="hla.html">HLA</a></li>
<li><a class="" href="platelet-specific.html">Platelet-Specific</a></li>
<li><a class="" href="granulocyte-specific.html">Granulocyte-Specific</a></li>
<li><a class="" href="role-of-blood-groups-in-transfusion.html">Role of Blood Groups in Transfusion</a></li>
<li><a class="" href="immunogenicity.html">Immunogenicity</a></li>
<li><a class="" href="antigen-prevalence.html">Antigen Prevalence</a></li>
<li class="book-part">Immunology &amp; Physiology</li>
<li><a class="" href="immunology.html">Immunology</a></li>
<li><a class="" href="immune-response.html">Immune response</a></li>
<li><a class="" href="primary-secondary.html">Primary &amp; Secondary</a></li>
<li><a class="" href="b-t-cells-macrophages.html">B &amp; T cells, Macrophages</a></li>
<li><a class="" href="genetics-1.html">Genetics</a></li>
<li><a class="" href="immunoglobulins.html">Immunoglobulins</a></li>
<li><a class="" href="classes-subclasses.html">Classes &amp; Subclasses</a></li>
<li><a class="" href="structure.html">Structure</a></li>
<li><a class="" href="properties.html">Properties</a></li>
<li><a class="" href="ag-ab-interactions.html">Ag-Ab Interactions</a></li>
<li><a class="" href="principles.html">Principles</a></li>
<li><a class="" href="testing-1.html">Testing</a></li>
<li><a class="" href="complement.html">Complement</a></li>
<li><a class="" href="pathway-mechanisms.html">Pathway Mechanisms</a></li>
<li><a class="" href="biologic-properties.html">Biologic Properties</a></li>
<li><a class="" href="physiology-pathophysiology.html">Physiology &amp; Pathophysiology</a></li>
<li><a class="" href="blood-physiology.html">Blood Physiology</a></li>
<li><a class="" href="circulation-volume.html">Circulation &amp; Volume</a></li>
<li><a class="" href="composition-function.html">Composition &amp; Function</a></li>
<li><a class="" href="cell-survival.html">Cell Survival</a></li>
<li><a class="" href="cell-metabolism.html">Cell Metabolism</a></li>
<li><a class="" href="hemostasis-coagulation.html">Hemostasis &amp; Coagulation</a></li>
<li><a class="" href="factors-disorders.html">Factors &amp; Disorders</a></li>
<li><a class="" href="plt-functions-disorders.html">PLT Functions &amp; Disorders</a></li>
<li><a class="" href="hdfn.html">HDFN</a></li>
<li><a class="" href="pathophysiology.html">Pathophysiology</a></li>
<li><a class="" href="detection.html">Detection</a></li>
<li><a class="" href="treatment.html">Treatment</a></li>
<li><a class="" href="prevention.html">Prevention</a></li>
<li><a class="" href="cytopenias-1.html">Cytopenias</a></li>
<li><a class="" href="anemia.html">Anemia</a></li>
<li><a class="" href="thrombocytopenia.html">Thrombocytopenia</a></li>
<li><a class="" href="neutropenia.html">Neutropenia</a></li>
<li><a class="" href="transplantation-1.html">Transplantation</a></li>
<li><a class="" href="solid-organ.html">Solid Organ</a></li>
<li><a class="active" href="hpc.html">HPC</a></li>
<li class="book-part">Serology &amp; Molecular</li>
<li><a class="" href="routine-tests.html">Routine Tests</a></li>
<li><a class="" href="blood-grouping.html">Blood Grouping</a></li>
<li><a class="" href="compatibility.html">Compatibility</a></li>
<li><a class="" href="antibody-detection.html">Antibody Detection</a></li>
<li><a class="" href="crossmatch.html">Crossmatch</a></li>
<li><a class="" href="ab-id-significance.html">Ab ID &amp; Significance</a></li>
<li><a class="" href="dat.html">DAT</a></li>
<li><a class="" href="reagents.html">Reagents</a></li>
<li><a class="" href="antiglobulin-sera.html">Antiglobulin Sera</a></li>
<li><a class="" href="blood-grouping-sera.html">Blood Grouping Sera</a></li>
<li><a class="" href="reagent-rbcs.html">Reagent RBCs</a></li>
<li><a class="" href="special-tests-reagents.html">Special Tests &amp; Reagents</a></li>
<li><a class="" href="enzymes.html">Enzymes</a></li>
<li><a class="" href="enhancement-media.html">Enhancement Media</a></li>
<li><a class="" href="lectins.html">Lectins</a></li>
<li><a class="" href="adsorptions.html">Adsorptions</a></li>
<li><a class="" href="elutions.html">Elutions</a></li>
<li><a class="" href="titrations-1.html">Titrations</a></li>
<li><a class="" href="cell-separations.html">Cell Separations</a></li>
<li><a class="" href="elisa.html">ELISA</a></li>
<li><a class="" href="molecular-techniques.html">Molecular Techniques</a></li>
<li><a class="" href="neutralization.html">Neutralization</a></li>
<li><a class="" href="thiol-reagents.html">Thiol Reagents</a></li>
<li><a class="" href="immunofluorescence.html">Immunofluorescence</a></li>
<li><a class="" href="solid-phase.html">Solid Phase</a></li>
<li><a class="" href="column-agglutination.html">Column Agglutination</a></li>
<li><a class="" href="chloroquine-diphosphate.html">Chloroquine Diphosphate</a></li>
<li><a class="" href="edta-glycine-acid.html">EDTA-Glycine Acid</a></li>
<li><a class="" href="quality-assurance.html">Quality Assurance</a></li>
<li><a class="" href="blood-samples.html">Blood Samples</a></li>
<li><a class="" href="reagents-1.html">Reagents</a></li>
<li><a class="" href="test-procedures.html">Test Procedures</a></li>
<li class="book-part">Transfusion Practice</li>
<li><a class="" href="indications.html">Indications</a></li>
<li><a class="" href="component-therapy.html">Component Therapy</a></li>
<li><a class="" href="adverse-effects.html">Adverse Effects</a></li>
<li><a class="" href="immunologic.html">Immunologic</a></li>
<li><a class="" href="nonimmunologic.html">Nonimmunologic</a></li>
<li><a class="" href="ttds.html">TTDs</a></li>
<li><a class="" href="apheresis-extracorporeal-circulation.html">Apheresis &amp; Extracorporeal Circulation</a></li>
<li><a class="" href="blood-administration-patient-blood-management.html">Blood Administration &amp; Patient Blood Management</a></li>
</ul>

        <div class="book-extra" style="display:none;">
          <p><a id="book-repo" href="https://github.com/brettmrice/Clinical-Blood-Bank/blob">View book source <i class="fab fa-github"></i></a></p>
        </div>
      </nav>
</div>
  </header><main class="col-sm-12 col-md-9 col-lg-7" id="content"><div id="hpc" class="section level1 unnumbered">
<h1>HPC<a class="anchor" aria-label="anchor" href="#hpc"><i class="fas fa-link"></i></a>
</h1>
<p><strong>Hematopoietic Progenitor Cell (HPC) Transplantation</strong>, often called stem cell transplant or bone marrow transplant, shares some principles with solid organ transplantation (like HLA matching), the immunology is fascinatingly different, with unique challenges like Graft-versus-Host Disease (GVHD) being a major focus</p>
<div id="the-goal-rebuilding-the-blood-and-immune-system" class="section level2 unnumbered">
<h2>
<strong>The Goal: Rebuilding the Blood and Immune System</strong><a class="anchor" aria-label="anchor" href="#the-goal-rebuilding-the-blood-and-immune-system"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Why Transplant?:</strong> HPC transplantation aims to replace a patient’s diseased or damaged hematopoietic system (the bone marrow and the blood/immune cells it produces) with healthy progenitor cells. It’s used to treat:
<ul>
<li>
<strong>Malignant Diseases:</strong> Leukemias (AML, ALL, CML, CLL), Lymphomas (Hodgkin, Non-Hodgkin), Multiple Myeloma. The goal is often to allow for high-dose chemotherapy/radiation to kill cancer cells (which also destroys the patient’s marrow) and then “rescue” the patient with new stem cells. Sometimes, the donor cells also exert a <strong>Graft-versus-Tumor (GvT)</strong> or <strong>Graft-versus-Leukemia (GvL)</strong> effect, where donor immune cells help eliminate residual cancer cells</li>
<li>
<strong>Bone Marrow Failure Syndromes:</strong> Aplastic Anemia, Fanconi Anemia</li>
<li>
<strong>Inherited Immune Deficiencies:</strong> Severe Combined Immunodeficiency (SCID), Wiskott-Aldrich Syndrome</li>
<li>
<strong>Hemoglobinopathies:</strong> Severe Sickle Cell Disease, Thalassemia Major</li>
<li>
<strong>Inherited Metabolic Disorders:</strong> Certain storage diseases</li>
</ul>
</li>
<li>
<strong>The Cells:</strong> <strong>Hematopoietic Progenitor Cells (HPCs)</strong> are multipotent stem cells residing primarily in the bone marrow. They have the remarkable ability to self-renew and differentiate into all lineages of blood and immune cells (red cells, white cells of all types, platelets). They are often identified and quantified by the presence of the <strong>CD34</strong> surface marker</li>
</ul>
</div>
<div id="sources-of-hpcs-1" class="section level2 unnumbered">
<h2>
<strong>Sources of HPCs</strong><a class="anchor" aria-label="anchor" href="#sources-of-hpcs-1"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Bone Marrow (BM):</strong> The traditional source. Collected via multiple aspirations from the donor’s posterior iliac crests under general or spinal anesthesia. Rich in stem cells but requires anesthesia and has some donor discomfort</li>
<li>
<strong>Peripheral Blood Stem Cells (PBSC):</strong> <strong>Most common source now.</strong> Donors receive injections of <strong>Granulocyte Colony-Stimulating Factor (G-CSF)</strong> +/- Plerixafor for several days. G-CSF “mobilizes” HPCs from the bone marrow into the peripheral circulation. The donor then undergoes <strong>apheresis</strong> (similar to platelet donation), where blood is drawn, passed through a machine to collect the CD34+ cells, and the remaining blood components are returned to the donor. Provides a higher yield of HPCs and usually faster engraftment than BM, with less donor discomfort than BM harvest</li>
<li>
<strong>Umbilical Cord Blood (UCB):</strong> Collected from the umbilical cord and placenta after birth. Contains a rich source of HPCs. Advantages include readily available (stored in cord blood banks), lower risk of transmitting infections, and <strong>less stringent HLA matching required</strong> due to the immunological naivety of cord blood T cells (leading to <strong>less Graft-versus-Host Disease</strong>). Disadvantages include lower cell dose (may be insufficient for larger adults), slower engraftment time, and inability to recall the donor for additional cells if needed</li>
</ul>
</div>
<div id="types-of-hpc-transplants-based-on-donor" class="section level2 unnumbered">
<h2>
<strong>Types of HPC Transplants (Based on Donor)</strong><a class="anchor" aria-label="anchor" href="#types-of-hpc-transplants-based-on-donor"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Autologous Transplant (“Auto”):</strong> The patient’s <em>own</em> HPCs are collected (usually PBSC) during a period of remission, stored (often cryopreserved), and then re-infused after the patient receives high-dose chemotherapy/radiation
<ul>
<li>
<strong>Advantage:</strong> No risk of rejection or GVHD</li>
<li>
<strong>Disadvantage:</strong> No Graft-versus-Tumor effect; higher risk of relapse if cancer cells were inadvertently collected with the stem cells</li>
</ul>
</li>
<li>
<strong>Allogeneic Transplant (“Allo”):</strong> HPCs are collected from a <strong>donor</strong> other than the patient
<ul>
<li>
<strong>Syngeneic:</strong> Donor is an identical twin (genetically identical). No GVHD risk, but also no GvT effect</li>
<li>
<strong>Related Donor:</strong> Donor is usually an HLA-matched sibling. Historically the preferred donor type</li>
<li>
<strong>Unrelated Donor (MUD - Matched Unrelated Donor):</strong> Donor found through international registries (like NMDP/Be The Match). Requires extensive HLA typing to find the best match</li>
<li>
<strong>Haploidentical Donor (“Haplo”):</strong> Donor shares exactly one HLA haplotype (usually a parent, child, or half-matched sibling). Requires special techniques (like T-cell depletion or post-transplant cyclophosphamide) to manage the high risk of rejection and GVHD due to the significant HLA mismatch. Becoming more common due to donor availability</li>
<li>
<strong>Cord Blood Donor:</strong> Uses unrelated UCB units</li>
</ul>
</li>
<li>
<strong>Key Difference from “Auto”:</strong> Allogeneic transplants introduce a <em>new</em> immune system from the donor. This allows for the beneficial <strong>Graft-versus-Tumor</strong> effect but carries the major risk of <strong>Graft-versus-Host Disease (GVHD)</strong> and <strong>rejection</strong>
</li>
</ul>
</div>
<div id="the-transplant-process" class="section level2 unnumbered">
<h2>
<strong>The Transplant Process</strong><a class="anchor" aria-label="anchor" href="#the-transplant-process"><i class="fas fa-link"></i></a>
</h2>
<ol style="list-style-type: decimal">
<li>
<strong>Conditioning Regimen</strong> Before receiving the HPC infusion, the patient undergoes intensive therapy
<ul>
<li>
<strong>Goals</strong>
<ul>
<li>Eradicate the underlying disease (e.g., leukemia)</li>
<li>Provide sufficient <strong>immunosuppression</strong> to prevent the recipient’s immune system from rejecting the donor stem cells (critical for allogeneic)</li>
<li>Create physical “space” in the bone marrow for the new stem cells to engraft</li>
</ul>
</li>
<li>
<strong>Methods:</strong> High-dose chemotherapy, Total Body Irradiation (TBI), or a combination. <strong>Reduced-Intensity Conditioning (RIC)</strong> regimens use lower doses, relying more on the GvT effect, allowing older or less fit patients to undergo transplant</li>
<li>
<strong>Consequence:</strong> Profound <strong>pancytopenia</strong> (low RBCs, WBCs, Platelets) and <strong>immunosuppression</strong>, making the patient highly vulnerable to infection and bleeding. Significant organ toxicities (mucositis, nausea, liver/kidney/lung damage) are common</li>
</ul>
</li>
<li>
<strong>HPC Infusion</strong> The collected HPC product (fresh or thawed cryopreserved) is infused intravenously into the recipient, much like a standard blood transfusion. This is often referred to as “Day 0”</li>
<li>
<strong>Engraftment</strong> The infused HPCs travel (“home”) to the bone marrow niches, begin to proliferate, and differentiate. Engraftment is defined by the sustained recovery of blood counts, typically:
<ul>
<li>Neutrophil engraftment: ANC &gt; 500/µL for 3 consecutive days (usually occurs ~10-21 days post-infusion, slower for cord blood)</li>
<li>Platelet engraftment: Platelet count &gt; 20,000/µL without transfusion support (often takes longer than neutrophils)</li>
</ul>
</li>
</ol>
</div>
<div id="immune-complications-the-major-challenges-of-allogeneic-hct" class="section level2 unnumbered">
<h2>
<strong>Immune Complications: The Major Challenges of Allogeneic HCT</strong><a class="anchor" aria-label="anchor" href="#immune-complications-the-major-challenges-of-allogeneic-hct"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Graft Rejection (Graft Failure):</strong> The recipient’s residual immune cells (especially T cells or NK cells) recognize the donor HPCs as foreign and destroy them. The graft fails to engraft, or engraftment is lost after initially occurring. More common with reduced-intensity conditioning, T-cell depleted grafts, or significant HLA mismatch. Leads to persistent pancytopenia</li>
<li>
<strong>Graft-versus-Host Disease (GVHD):</strong> <strong>The hallmark complication of allogeneic HCT.</strong> Occurs when mature, immunocompetent <strong>donor T lymphocytes</strong> (present in the HPC graft) recognize the <strong>recipient’s tissues</strong> as foreign (due to differences in HLA and minor histocompatibility antigens) and mount an immune attack against them
<ul>
<li>
<strong>Acute GVHD (aGVHD):</strong> Typically occurs within the first 100 days post-transplant. Primarily affects:
<ul>
<li>
<strong>Skin:</strong> Rash (maculopapular)</li>
<li>
<strong>Liver:</strong> Jaundice, elevated liver enzymes</li>
<li>
<strong>Gastrointestinal Tract:</strong> Diarrhea (often profuse, watery, or bloody), nausea, vomiting, abdominal pain</li>
<li>Severity is graded (I-IV). Can be life-threatening</li>
</ul>
</li>
<li>
<strong>Chronic GVHD (cGVHD):</strong> Usually occurs &gt;100 days post-transplant (can occur earlier or evolve from acute GVHD). Can affect almost any organ system, often resembling autoimmune/collagen vascular diseases. Common features include skin changes (sclerosis, pigment changes), dry eyes/mouth (sicca syndrome), lung problems (bronchiolitis obliterans), liver dysfunction, joint contractures, GI issues. Major cause of late morbidity and mortality</li>
<li>
<strong>Prevention/Treatment:</strong> Prophylactic immunosuppression (similar drugs to SOT: calcineurin inhibitors, methotrexate, mycophenolate, etc.) is standard. Treatment involves increasing immunosuppression (steroids first-line), potentially adding other agents (Rituximab, IVIg, ECP - extracorporeal photopheresis)</li>
</ul>
</li>
</ul>
</div>
<div id="hla-matching-critical-for-success" class="section level2 unnumbered">
<h2>
<strong>HLA Matching: Critical for Success</strong><a class="anchor" aria-label="anchor" href="#hla-matching-critical-for-success"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Importance:</strong> Minimizing HLA differences between donor and recipient is paramount for <strong>allogeneic</strong> HCT to reduce the risk and severity of both <strong>GVHD</strong> and <strong>graft rejection</strong>
</li>
<li>
<strong>Required Typing:</strong> High-resolution typing (identifying specific alleles) for <strong>HLA-A, -B, -C, and -DRB1</strong> is considered essential. Matching at other loci (DQB1, DPB1) is increasingly considered</li>
<li>
<strong>Donor Hierarchy</strong>
<ol style="list-style-type: decimal">
<li>HLA-matched sibling (identical twin is perfect but rare)</li>
<li>HLA-matched unrelated donor (MUD) (8/8 or 10/10 match preferred)</li>
<li>HLA-mismatched unrelated donor</li>
<li>Umbilical Cord Blood unit(s) (less stringent matching acceptable)</li>
<li>Haploidentical relative</li>
</ol>
</li>
</ul>
</div>
<div id="abo-compatibility-secondary-but-important" class="section level2 unnumbered">
<h2>
<strong>ABO Compatibility: Secondary but Important</strong><a class="anchor" aria-label="anchor" href="#abo-compatibility-secondary-but-important"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>ABO antigens are <strong>not</strong> expressed strongly on HPCs themselves, so ABO incompatibility is <strong>not</strong> a barrier to performing the transplant (unlike SOT). However, it has significant implications for <strong>transfusion support</strong> and potential <strong>immune hemolysis</strong> during and after transplant</li>
<li>
<strong>Types of ABO Incompatibility</strong>
<ul>
<li>
<strong>Major:</strong> Donor has ABO antigens recipient lacks (e.g., Group A donor -&gt; Group O recipient). Recipient has pre-formed anti-A/anti-B (isohemagglutinins) that can attack donor RBCs produced <em>after</em> engraftment OR passenger lymphocytes in the graft making antibody. Risk of immediate or delayed hemolysis. HPC product may be plasma-reduced or RBC-depleted before infusion</li>
<li>
<strong>Minor:</strong> Recipient has ABO antigens donor lacks (e.g., Group O donor -&gt; Group A recipient). Donor graft contains plasma with anti-A/anti-B (isohemagglutinins) from the donor OR donor B cells that will produce anti-A/anti-B after engraftment. Risk of hemolysis of <em>recipient</em> RBCs shortly after infusion (“passenger lymphocyte syndrome”) or later as donor immune system takes over. HPC product may be plasma-reduced</li>
<li>
<strong>Bidirectional:</strong> Both major and minor incompatibility exist (e.g., Group A donor -&gt; Group B recipient). Risks of both scenarios</li>
</ul>
</li>
<li>
<strong>Blood Bank Management:</strong> Requires careful planning for transfusion support around the time of transplant, often needing specific ABO group products depending on the incompatibility and phase of engraftment (e.g., using Group O RBCs and Group AB plasma initially for major incompatibility). Monitoring for hemolysis is crucial. Recipient’s blood type may eventually change to the donor’s type after full engraftment</li>
</ul>
</div>
<div id="other-complications-1" class="section level2 unnumbered">
<h2>
<strong>Other Complications</strong><a class="anchor" aria-label="anchor" href="#other-complications-1"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Infections:</strong> Profound and prolonged immunosuppression leads to high risk of bacterial, fungal, viral (CMV, EBV, Adenovirus, BK virus), and protozoal infections. Requires intensive monitoring and prophylactic/pre-emptive therapies</li>
<li>
<strong>Organ Toxicity:</strong> From conditioning regimens (mucositis, VOD/SOS - hepatic veno-occlusive disease/sinusoidal obstruction syndrome, lung injury, kidney injury, cardiotoxicity)</li>
<li>
<strong>Secondary Malignancies:</strong> Increased long-term risk due to radiation, chemotherapy, and chronic immunosuppression/GVHD</li>
<li>
<strong>Endocrine Issues:</strong> Hypothyroidism, hypogonadism, infertility, growth impairment in children</li>
<li>
<strong>Relapse:</strong> Return of the original underlying disease remains a major cause of treatment failure</li>
</ul>
</div>
<div id="blood-bank-role-essential-support" class="section level2 unnumbered">
<h2>
<strong>Blood Bank Role: Essential Support</strong><a class="anchor" aria-label="anchor" href="#blood-bank-role-essential-support"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>HLA Typing Coordination:</strong> Working with specialized HLA laboratories</li>
<li>
<strong>Blood Product Support:</strong> Providing necessary RBCs and Platelets during the period of marrow aplasia post-conditioning. <strong>CRITICAL Requirements</strong>
<ul>
<li>
<strong>Irradiation:</strong> <strong>Mandatory</strong> for all cellular components to prevent Transfusion-Associated GVHD (TA-GVHD) caused by viable donor lymphocytes in the blood product attacking the immunocompromised recipient</li>
<li>
<strong>CMV-Safe:</strong> Leukocyte reduction or CMV-seronegative products are essential to prevent CMV transmission</li>
<li>
<strong>Leukocyte Reduction:</strong> Standard practice</li>
<li>
<strong>Managing ABO Incompatibility:</strong> Providing appropriate ABO group components pre- and post-engraftment based on the type of incompatibility (see above)</li>
</ul>
</li>
<li>
<strong>Therapeutic Apheresis:</strong> Plasma exchange for TTP post-transplant, ECP for GVHD treatment</li>
<li>
<strong>HPC Collection/Processing/Cryopreservation:</strong> In centers where the Blood Bank/Transfusion Service manages the HPC laboratory. Includes CD34+ cell enumeration, processing (e.g., plasma reduction, RBC depletion), adding cryoprotectant (DMSO), controlled-rate freezing, and storage in liquid nitrogen. Thawing at the bedside prior to infusion</li>
</ul>
</div>
<div id="key-terms-71" class="section level2 unnumbered">
<h2>
<strong>Key Terms</strong><a class="anchor" aria-label="anchor" href="#key-terms-71"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Hematopoietic Progenitor Cells (HPCs):</strong> Multipotent stem cells that give rise to all blood cell lineages</li>
<li>
<strong>CD34:</strong> Surface marker commonly used to identify and quantify HPCs</li>
<li>
<strong>Mobilization:</strong> Process of stimulating HPCs to move from bone marrow into peripheral blood (using G-CSF)</li>
<li>
<strong>Apheresis:</strong> Procedure to collect specific blood components (like PBSCs) while returning the rest to the donor</li>
<li>
<strong>Conditioning Regimen:</strong> High-dose chemotherapy and/or radiation given before HPC infusion to eradicate disease and suppress the recipient’s immune system</li>
<li>
<strong>Engraftment:</strong> The process where infused HPCs establish themselves in the bone marrow and begin producing new blood cells</li>
<li>
<strong>Autologous Transplant:</strong> Using the patient’s own HPCs</li>
<li>
<strong>Allogeneic Transplant:</strong> Using HPCs from a donor</li>
<li>
<strong>Graft-versus-Host Disease (GVHD):</strong> Immune attack by donor T cells against recipient tissues; major complication of allogeneic HCT</li>
<li>
<strong>Graft-versus-Tumor (GvT) / Graft-versus-Leukemia (GvL):</strong> Beneficial effect where donor immune cells eliminate residual cancer cells in the recipient</li>
<li>
<strong>HLA Matching:</strong> Assessing compatibility of Human Leukocyte Antigens between donor and recipient; crucial for allogeneic HCT success</li>
<li>
<strong>Chimerism:</strong> The presence of cells from two genetically distinct individuals (donor and recipient) in one person after transplant</li>
<li>
<strong>Irradiation (Blood Products):</strong> Treatment to inactivate T lymphocytes in cellular blood components to prevent TA-GVHD</li>
<li>
<strong>Veno-occlusive Disease (VOD) / Sinusoidal Obstruction Syndrome (SOS):</strong> Serious liver complication, often related to conditioning toxicity</li>
</ul>
</div>
</div>



<!-- Scoll to TOC element -->
<script defer>
  // adjust TOC scroll to selected element/topic
  function scroll_to_element() {
    header_height = document.getElementsByTagName('header')[0].offsetHeight/2;
    toc_element_position = document.querySelector('.book-toc > li > a.active').offsetTop;
    if(document.querySelector('.book-toc > li > a.active').offsetLeft == 0) {
      toc_element_position1 = document.querySelector('.book-toc > li > a.active').offsetParent.offsetTop;
      toc_element_position2 = document.querySelector('.book-toc > li > a.active').offsetParent.offsetHeight;
      toc_element_position = toc_element_position1 + toc_element_position2;
    }
    document.getElementsByTagName('header')[0].scrollTo(0, toc_element_position - header_height, 'smooth');
  }
  window.onload = scroll_to_element();
  
  // hide those labes that take up multiple lines
  l = [];
  function hide_label() {
    document
      .querySelectorAll('.book-toc > li')
      .forEach(elem => {
        window
          .getComputedStyle(elem)
          .textTransform === "uppercase" 
          && 
          !elem.classList
          .contains('book-part') 
          ? l.push(elem) 
          : '';
      });
  }
  hide_label();
  head = document.getElementsByTagName('header')[0];
  head.addEventListener('scroll', () => {
    count = 0;
    prev_elem = '';
    l.forEach((elem) => {
      if(count === 0) {
        initial_y = elem.getBoundingClientRect().y + 20;
        count = 1;
      } else {
        if(elem.getBoundingClientRect().y < initial_y) {
          prev_elem.classList.add('hide_label');
        } else {
          prev_elem.classList.remove('hide_label');
        }
      }
      prev_elem = elem;
    });
  });
</script><div class="chapter-nav">
<div class="prev"><a href="solid-organ.html">Solid Organ</a></div>
<div class="next"><a href="routine-tests.html">Routine Tests</a></div>
</div></main><div class="col-md-3 col-lg-2 d-none d-md-block sidebar sidebar-chapter">
    <nav id="toc" data-toggle="toc" aria-label="On this page"><h2>On this page</h2>
      <ul class="nav navbar-nav">
<li><a class="nav-link" href="#hpc">HPC</a></li>
<li><a class="nav-link" href="#the-goal-rebuilding-the-blood-and-immune-system">The Goal: Rebuilding the Blood and Immune System</a></li>
<li><a class="nav-link" href="#sources-of-hpcs-1">Sources of HPCs</a></li>
<li><a class="nav-link" href="#types-of-hpc-transplants-based-on-donor">Types of HPC Transplants (Based on Donor)</a></li>
<li><a class="nav-link" href="#the-transplant-process">The Transplant Process</a></li>
<li><a class="nav-link" href="#immune-complications-the-major-challenges-of-allogeneic-hct">Immune Complications: The Major Challenges of Allogeneic HCT</a></li>
<li><a class="nav-link" href="#hla-matching-critical-for-success">HLA Matching: Critical for Success</a></li>
<li><a class="nav-link" href="#abo-compatibility-secondary-but-important">ABO Compatibility: Secondary but Important</a></li>
<li><a class="nav-link" href="#other-complications-1">Other Complications</a></li>
<li><a class="nav-link" href="#blood-bank-role-essential-support">Blood Bank Role: Essential Support</a></li>
<li><a class="nav-link" href="#key-terms-71">Key Terms</a></li>
</ul>

      <div class="book-extra">
        <ul class="list-unstyled">
<li><a id="book-source" href="https://github.com/brettmrice/Clinical-Blood-Bank/blob/blob/main/Rmd/03-B-05-b.Rmd">View source <i class="fab fa-github"></i></a></li>
          <li><a id="book-edit" href="https://github.com/brettmrice/Clinical-Blood-Bank/blob/edit/main/Rmd/03-B-05-b.Rmd" target="_blank">Edit this page <i class="fab fa-github"></i></a></li>
          <li><a id="buymeacoffee" href="https://buymeacoffee.com/bloodcellid" target="_blank">NEED Caffeine</a></li>
        </ul>
</div>
    </nav>
</div>

</div>
</div> <!-- .container -->

<footer class="bg-primary text-light mt-5"><div class="container"><div class="row">

  <div class="col-12 col-md-6 mt-3" style="text-align: center; flex: 100%; max-width: 100%;">
    <p>Written by Brett M. Rice | Updated 2025-04-07 | Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div>

  <!--div class="col-12 col-md-6 mt-3">
    <p>Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div-->

</div></div>
</footer>
</body>
</html>
